Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis

BACKGROUND: Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. METHODS: Surv...

Descripción completa

Detalles Bibliográficos
Autores principales: Jiao, Dechuang, Zhang, Jingyang, Zhu, Jiujun, Guo, Xuhui, Yang, Yue, Xiao, Hui, Liu, Zhenzhen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868017/
https://www.ncbi.nlm.nih.gov/pubmed/33549037
http://dx.doi.org/10.1186/s12885-021-07855-z
_version_ 1783648386783641600
author Jiao, Dechuang
Zhang, Jingyang
Zhu, Jiujun
Guo, Xuhui
Yang, Yue
Xiao, Hui
Liu, Zhenzhen
author_facet Jiao, Dechuang
Zhang, Jingyang
Zhu, Jiujun
Guo, Xuhui
Yang, Yue
Xiao, Hui
Liu, Zhenzhen
author_sort Jiao, Dechuang
collection PubMed
description BACKGROUND: Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. METHODS: Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. RESULTS: Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). CONCLUSIONS: Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients.
format Online
Article
Text
id pubmed-7868017
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-78680172021-02-08 Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis Jiao, Dechuang Zhang, Jingyang Zhu, Jiujun Guo, Xuhui Yang, Yue Xiao, Hui Liu, Zhenzhen BMC Cancer Research Article BACKGROUND: Previous studies have reported poor survival rates in inflammatory breast cancer (IBC) patients than non-inflammatory local advanced breast cancer (non-IBC) patients. However, until now, the survival rate of IBC and other T4 non-IBC (T4-non-IBC) patients remains unexplored. METHODS: Surveillance, Epidemiology, and End Results (SEER) database was searched to identify cases with confirmed non-metastatic IBC and T4-non-IBC who had received surgery, chemotherapy, and radiotherapy between 2010 and 2015. IBC was defined as per the American Joint Committee on Cancer (AJCC) 7th edition. Breast Cancer-Specific Survival (BCSS) was estimated by plotting the Kaplan-Meier curve and compared across groups by using the log-rank test. Cox model was constructed to determine the association between IBC and BCSS after adjusting for age, race, stage of disease, tumor grade and surgery type. RESULTS: Out of a total of 1986 patients, 37.1% had IBC and mean age was 56.6 ± 12.4. After a median follow-up time of 28 months, 3-year BCSS rate for IBC and T4-non-IBC patients was 81.4 and 81.9%, respectively (log-rank p = 0.398). The 3-year BCSS rate in HR−/HER2+ cohort was higher for IBC patients than T4-non-IBC patients (89.5% vs. 80.8%; log-rank p = 0.028), and in HR−/HER2- cohort it was significantly lower for IBC patients than T4-non-IBC patients (57.4% vs. 67.5%; log-rank p = 0.010). However, it was identical between IBC and T4-non-IBC patients in both HR+/HER2- (85.0% vs. 85.3%; log-rank p = 0.567) and HR+/HER2+ (93.6% vs. 91.0%, log-rank p = 0.510) cohorts. After adjusting for potential confounding variables, we observed that IBC is a significant independent predictor for survival of HR−/HER2+ cohort (hazards ratio [HR] = 0.442; 95% CI: 0.216–0.902; P = 0.025) and HR−/HER2- cohort (HR = 1.738; 95% CI: 1.192–2.534; P = 0.004). CONCLUSIONS: Patients with IBC and T4-non-IBC had a similar BCSS in the era of modern systemic treatment. In IBC patients, the HR−/HER2+ subtype is associated with a better outcome, and HR−/HER2- subtype is associated with poorer outcomes as compared to the T4-non-IBC patients. BioMed Central 2021-02-06 /pmc/articles/PMC7868017/ /pubmed/33549037 http://dx.doi.org/10.1186/s12885-021-07855-z Text en © The Author(s) 2021 Open AccessThis article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research Article
Jiao, Dechuang
Zhang, Jingyang
Zhu, Jiujun
Guo, Xuhui
Yang, Yue
Xiao, Hui
Liu, Zhenzhen
Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
title Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
title_full Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
title_fullStr Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
title_full_unstemmed Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
title_short Comparison of survival in non-metastatic inflammatory and other T4 breast cancers: a SEER population-based analysis
title_sort comparison of survival in non-metastatic inflammatory and other t4 breast cancers: a seer population-based analysis
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7868017/
https://www.ncbi.nlm.nih.gov/pubmed/33549037
http://dx.doi.org/10.1186/s12885-021-07855-z
work_keys_str_mv AT jiaodechuang comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis
AT zhangjingyang comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis
AT zhujiujun comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis
AT guoxuhui comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis
AT yangyue comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis
AT xiaohui comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis
AT liuzhenzhen comparisonofsurvivalinnonmetastaticinflammatoryandothert4breastcancersaseerpopulationbasedanalysis